Fintel reports that on December 1, 2025, Truist Securities initiated coverage of Immunome (NasdaqCM:IMNM) with a Buy recommendation.
Analyst Price Forecast Suggests 32.90% Upside
As of November 17, 2025, the average one-year price target for Immunome is $24.48/share. The forecasts range from a low of $18.18 to a high of $39.90. The average price target represents an increase of 32.90% from its latest reported closing price of $18.42 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Immunome is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is 6.55.
What is the Fund Sentiment?
There are 312 funds or institutions reporting positions in Immunome. This is an increase of 19 owner(s) or 6.48% in the last quarter. Average portfolio weight of all funds dedicated to IMNM is 0.16%, an increase of 9.10%. Total shares owned by institutions increased in the last three months by 13.10% to 99,898K shares. 
The put/call ratio of IMNM is 0.07, indicating a bullish outlook.
What are Other Shareholders Doing?
T. Rowe Price Investment Management holds 8,418K shares representing 9.18% ownership of the company. In its prior filing, the firm reported owning 8,275K shares , representing an increase of 1.70%. The firm increased its portfolio allocation in IMNM by 24.00% over the last quarter.
Redmile Group holds 5,023K shares representing 5.48% ownership of the company. In its prior filing, the firm reported owning 4,872K shares , representing an increase of 3.01%. The firm increased its portfolio allocation in IMNM by 18.68% over the last quarter.
Point72 Asset Management holds 4,825K shares representing 5.26% ownership of the company. In its prior filing, the firm reported owning 4,686K shares , representing an increase of 2.87%. The firm increased its portfolio allocation in IMNM by 10.52% over the last quarter.
Enavate Sciences GP holds 4,769K shares representing 5.20% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 4,079K shares representing 4.45% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
